A disorder characterized by non-neoplastic bone formation in soft tissues. It usually follows blunt trauma and bleeding in the deep soft tissues.
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding myositis ossificans is largely due to its rarity, affecting fewer than 1 in 2 million people worldwide. This extreme rarity restricts the ability to conduct large-scale clinical studies, leading to gaps in understanding its clinical features and genetic basis.
To navigate myositis ossificans, consider consulting a specialist in rare bone disorders or a geneticist with experience in connective tissue diseases. While no specific patient organizations are identified, the Genetic and Rare Diseases Information Center (GARD) offers resources and support for rare conditions. You may also explore opportunities to participate in clinical trials listed at ClinicalTrials.gov, which can provide access to cutting-edge research and potential treatments.
Currently, there are several orphan drugs designated for myositis ossificans, including palovarotene and others in development. There are also 7 active clinical trials, which can provide opportunities for participation in research aimed at better understanding and treating this condition. For more information on these trials, visit ClinicalTrials.gov and search for myositis ossificans.
Actionable guidance for navigating care for myositis ossificans
To navigate myositis ossificans, consider consulting a specialist in rare bone disorders or a geneticist with experience in connective tissue diseases. While no specific patient organizations are identified, the Genetic and Rare Diseases Information Center (GARD) offers resources and support for rare conditions. You may also explore opportunities to participate in clinical trials listed at ClinicalTrials.gov, which can provide access to cutting-edge research and potential treatments.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding myositis ossificans is largely due to its rarity, affecting fewer than 1 in 2 million people worldwide. This extreme rarity restricts the ability to conduct large-scale clinical studies, leading to gaps in understanding its clinical features and genetic basis.
To navigate myositis ossificans, consider consulting a specialist in rare bone disorders or a geneticist with experience in connective tissue diseases. While no specific patient organizations are identified, the Genetic and Rare Diseases Information Center (GARD) offers resources and support for rare conditions. You may also explore opportunities to participate in clinical trials listed at ClinicalTrials.gov, which can provide access to cutting-edge research and potential treatments.
Currently, there are several orphan drugs designated for myositis ossificans, including palovarotene and others in development. There are also 7 active clinical trials, which can provide opportunities for participation in research aimed at better understanding and treating this condition. For more information on these trials, visit ClinicalTrials.gov and search for myositis ossificans.
Actionable guidance for navigating care for myositis ossificans
To navigate myositis ossificans, consider consulting a specialist in rare bone disorders or a geneticist with experience in connective tissue diseases. While no specific patient organizations are identified, the Genetic and Rare Diseases Information Center (GARD) offers resources and support for rare conditions. You may also explore opportunities to participate in clinical trials listed at ClinicalTrials.gov, which can provide access to cutting-edge research and potential treatments.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding myositis ossificans is largely due to its rarity, affecting fewer than 1 in 2 million people worldwide. This extreme rarity restricts the ability to conduct large-scale clinical studies, leading to gaps in understanding its clinical features and genetic basis.
To navigate myositis ossificans, consider consulting a specialist in rare bone disorders or a geneticist with experience in connective tissue diseases. While no specific patient organizations are identified, the Genetic and Rare Diseases Information Center (GARD) offers resources and support for rare conditions. You may also explore opportunities to participate in clinical trials listed at ClinicalTrials.gov, which can provide access to cutting-edge research and potential treatments.
Currently, there are several orphan drugs designated for myositis ossificans, including palovarotene and others in development. There are also 7 active clinical trials, which can provide opportunities for participation in research aimed at better understanding and treating this condition. For more information on these trials, visit ClinicalTrials.gov and search for myositis ossificans.
Actionable guidance for navigating care for myositis ossificans
To navigate myositis ossificans, consider consulting a specialist in rare bone disorders or a geneticist with experience in connective tissue diseases. While no specific patient organizations are identified, the Genetic and Rare Diseases Information Center (GARD) offers resources and support for rare conditions. You may also explore opportunities to participate in clinical trials listed at ClinicalTrials.gov, which can provide access to cutting-edge research and potential treatments.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.